Abstract
Background: It is well-known and augmented frequency of pernicious anemia in already diagnosed subjects of multiple myeloma (MM). The most frequent reason of vitamin B12 insufficiency is pernicious anemia. Diagnosis of vita: B12 insufficiency is made with presenting complaints of subject, physical sign and symptoms, and laboratory investigation explain decrease in serum vita: B12 level which is most probably present in subjects of MM. Pernicious anemia along with peripheral neuropathy are repeatedly correlates with MM and vita: B12 insufficiency.
Methods: An existing study was cross sectional study in which we select 250 subjects of MM on OPD basis from multiple cancer hospitals in Pakistan. The selected patients are already diagnosed as MM with their lab findings of pteroylglutamic acid (folate) in serum and in red blood cells (RBC). Serum Folate levels were assessed on commercially available Folate ELISA (Cortez Diagnostic USA). Red cell folate levels were evaluated on commercially available Folate RBC electro cheiluminescence immunoassay (quantitative) ECLIA (Roche Diagnostics International Switzerland), serum Vita: B12 levels were estimated on commercially presented Vita: B 12 ELISA Kit (Abnova USA) Methylmalonic Acid in Serum / Plasma / Urine ELISA Kit (RECIPE Chemicals, Munich / Germany) and Homocysteine HPLC Assay (Eagle Biosciences, Inc. Germany).
Results: Total 250 patients were finalizing on the basis of clinical criterion and laboratory evaluation as MM out of which 73 (29.2%) having laboratory values showed cyanocobalamin deficiency and the residual 177 subjects (70.8%) are clear.